IL159475A0 - Spherical protein particles, compositions containing the same and methods for the production thereof - Google Patents

Spherical protein particles, compositions containing the same and methods for the production thereof

Info

Publication number
IL159475A0
IL159475A0 IL15947502A IL15947502A IL159475A0 IL 159475 A0 IL159475 A0 IL 159475A0 IL 15947502 A IL15947502 A IL 15947502A IL 15947502 A IL15947502 A IL 15947502A IL 159475 A0 IL159475 A0 IL 159475A0
Authority
IL
Israel
Prior art keywords
production
methods
same
compositions containing
protein particles
Prior art date
Application number
IL15947502A
Other languages
English (en)
Original Assignee
Altus Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altus Biologics Inc filed Critical Altus Biologics Inc
Publication of IL159475A0 publication Critical patent/IL159475A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/60—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • C30B7/06—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent using non-aqueous solvents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
IL15947502A 2001-06-21 2002-06-21 Spherical protein particles, compositions containing the same and methods for the production thereof IL159475A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29998901P 2001-06-21 2001-06-21
PCT/US2002/019870 WO2003000014A2 (en) 2001-06-21 2002-06-21 Spherical protein particles and methods of making and using them

Publications (1)

Publication Number Publication Date
IL159475A0 true IL159475A0 (en) 2004-06-01

Family

ID=23157185

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15947502A IL159475A0 (en) 2001-06-21 2002-06-21 Spherical protein particles, compositions containing the same and methods for the production thereof

Country Status (8)

Country Link
US (2) US7998477B2 (xx)
EP (1) EP1492554B1 (xx)
JP (1) JP2005500304A (xx)
AU (1) AU2002322295C1 (xx)
CA (1) CA2451185A1 (xx)
IL (1) IL159475A0 (xx)
NZ (1) NZ530700A (xx)
WO (1) WO2003000014A2 (xx)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100923514B1 (ko) * 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
JP2005500304A (ja) 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド 球状タンパク質粒子およびそれらの作製方法および使用方法
JP4161101B2 (ja) * 2002-06-21 2008-10-08 独立行政法人 日本原子力研究開発機構 生体高分子の結晶育成装置
SG135204A1 (en) 2003-07-18 2007-09-28 Baxter Int Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
JP2005241389A (ja) * 2004-02-25 2005-09-08 Ochiyanomizu Jiyoshi Univ 蛍光標識糖鎖の特異的固定化試薬および固定化方法
PT1758558E (pt) 2004-05-12 2013-12-05 Baxter Healthcare Sa Microesferas contendo oligonucleótidos, sua utilização para o fabrico de um medicamento para o tratamento de diabetes do tipo 1
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1765294B1 (en) 2004-05-12 2008-09-24 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
MXPA06012992A (es) 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
BRPI0517457A (pt) 2004-10-22 2008-10-07 Amgen Inc métodos para reenovelamento de anticorpos recombinantes
US7956160B2 (en) * 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
SI1948259T1 (sl) * 2005-10-26 2017-07-31 Genesis Technologies Limited Acelularni bioabsorbljivi tkivni regeneracijski matriksi, proizvedeni z inkubiranjem acelularnih proizvodov krvi
JP5147699B2 (ja) * 2005-12-20 2013-02-20 富士フイルム株式会社 タンパク質ナノ粒子およびその使用
WO2007114262A1 (ja) 2006-03-29 2007-10-11 Fujifilm Corporation カゼインナノ粒子
US7964574B2 (en) 2006-08-04 2011-06-21 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
US8808747B2 (en) 2007-04-17 2014-08-19 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
JP2008285432A (ja) 2007-05-16 2008-11-27 Fujifilm Corp 皮膚外用剤
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009005709A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles
US20090022805A1 (en) * 2007-06-28 2009-01-22 Joram Slager Polypeptide microparticles having sustained release characteristics, methods and uses
KR100845009B1 (ko) * 2007-08-07 2008-07-08 한국생명공학연구원 전하를 띠는 물질이 고착된 다공성 고분자 입자 및 그제조방법
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
DK2774608T3 (da) 2008-06-16 2020-01-13 Pfizer Lægemiddelladede polymere nanopartikler og fremgangsmåder til fremstilling og anvendelse deraf
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
EP2376522A4 (en) * 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
FR2938542B1 (fr) 2008-11-18 2013-06-14 Sang Bourgogne Franche Comte Ets Franc Proteine cd20 tronquee, deltacd20
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
US8529933B2 (en) 2009-07-27 2013-09-10 Warsaw Orthopedic, Inc. Biphasic calcium phosphate cement for drug delivery
JP5491119B2 (ja) 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
EA201290499A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами
MX336473B (es) 2010-02-11 2016-01-20 Hoffmann La Roche Ensayo mediante adcc nk facs tridimensional.
US9643996B2 (en) 2011-11-04 2017-05-09 Battelle Memorial Institute Processes for producing protein microparticles
CN105688188A (zh) 2011-11-18 2016-06-22 瑞泽恩制药公司 聚合物蛋白微粒
US20150177115A1 (en) 2012-04-06 2015-06-25 Slingshot Biosciences Hydrogel particles with tunable optical properties
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
HUE043998T2 (hu) 2012-09-17 2019-09-30 Pfizer Eljárás terápiás nanorészecskék elõállítására
US9474803B2 (en) 2012-11-27 2016-10-25 Alteogen Inc. Composition for stabilizing fusion protein in which protein and FC domain are fused
CN103018446B (zh) * 2012-12-24 2014-08-20 青岛汉唐生物科技有限公司 用于检测甲型肝炎病毒抗体的方法、检测用的试剂盒及其制备方法
BR112016004054A2 (pt) * 2013-08-26 2017-09-12 Ps Therapies Ltd composições e métodos para o tratamento de condições nasais
WO2015058173A1 (en) * 2013-10-18 2015-04-23 Abbvie Inc. Stable solid units and methods of making the same
CA2942859A1 (en) 2014-03-14 2015-09-17 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
US10525122B2 (en) 2014-07-18 2020-01-07 Km Biologics Co., Ltd. Vaccine containing virus-like particles
EP3179985A1 (en) * 2014-08-14 2017-06-21 Brown University Compositions for stabilizing and delivering proteins
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
KR102436976B1 (ko) 2015-02-09 2022-08-25 슬링샷 바이오사이언시즈 인코포레이티드 튜닝가능한 광 특성을 갖는 하이드로겔 입자 및 이를 사용하기 위한 방법
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
EP3278102B1 (en) 2015-04-24 2021-12-29 Colgate-Palmolive Company Porous protein particles as carriers for actives
WO2017219974A1 (zh) 2016-06-22 2017-12-28 本康生物制药（深圳）有限公司 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用
CN108504638B (zh) * 2017-02-28 2021-09-17 中国科学院过程工程研究所 一种口蹄疫灭活病毒抗原纯化或储存的方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CN113238039B (zh) * 2018-03-07 2023-03-31 深圳市伯劳特生物制品有限公司 一种检测试剂盒
KR20210124228A (ko) * 2018-12-31 2021-10-14 라니 테라퓨틱스, 엘엘씨 삼킬 수 있는 약물 전달 장치를 사용하여 장관의 내강으로 약물을 전달하기 위한 치료제 제제 및 방법
US10993459B2 (en) 2019-09-23 2021-05-04 Ralph Yoder Method for unlocking bioactive proteins
KR20220104797A (ko) 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
WO2021150838A1 (en) 2020-01-24 2021-07-29 Slingshot Biosciences, Inc. Compositions and methods for cell-like calibration particles
WO2021177996A1 (en) * 2020-03-02 2021-09-10 Northwestern University Fit-flares for detection of intracellular analytes in live cells
KR20230029612A (ko) 2020-05-04 2023-03-03 슬링샷 바이오사이언시즈 인코포레이티드 다중 검정을 위한 수동 광학 바코딩용 조성물 및 방법
TW202237070A (zh) 2020-11-25 2022-10-01 美商再生元醫藥公司 使用非水性膜乳化之持續釋放調配物
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4334024A (en) 1980-11-03 1982-06-08 Sarjit Johal Preparation and crystallization of fraction I protein from plant sources
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DE3419782C1 (de) 1984-05-26 1985-11-14 Gödecke AG, 1000 Berlin Sphaerische Proteinpartikel mit immunadsorbierenden Eigenschaften und Verfahren zu deren Herstellung
US6727278B1 (en) * 1986-08-27 2004-04-27 Dms Pharmaceutical Inc. Pharmaceutically active agents that impede amyloid formation in vivo
EP0506866B1 (en) 1989-12-21 1993-10-20 Novo Nordisk A/S Method for crystallization of enzymes
US5780599A (en) 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
US5618710A (en) 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5751453A (en) * 1991-12-06 1998-05-12 Ncr Corporation Liquid crystal display with pen-input capability
EP0646000A4 (en) * 1992-11-16 1997-05-02 Univ Mercer COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
AU6960696A (en) 1995-08-30 1997-03-19 Ariad Pharmaceuticals, Inc. Crystalline zap family proteins
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US5932212A (en) 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
EP2311436A1 (en) * 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
ATE325868T1 (de) 1999-03-05 2006-06-15 Genencor Int Verfahren zur schnellen herstellung von crystallen mit wünschenswerter morphologie
AU782916B2 (en) * 1999-06-09 2005-09-08 Robert E. Sievers Supercritical fluid-assisted nebulization and bubble drying
ES2184716T3 (es) 1999-06-10 2003-04-16 Max Planck Gesellschaft Encapsulacion de cristales por medio de recubrimientos multicapa.
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
FR2802445B1 (fr) * 1999-12-15 2002-02-15 Separex Sa Procede et dispositif de captage de fines particules par piegeage au sein d'un melange solide de type neige carbonique
US6562952B1 (en) * 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
KR100923514B1 (ko) * 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
EP1801123A3 (en) * 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
JP2005500304A (ja) 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド 球状タンパク質粒子およびそれらの作製方法および使用方法
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems

Also Published As

Publication number Publication date
CA2451185A1 (en) 2003-01-03
AU2002322295C1 (en) 2008-12-18
EP1492554B1 (en) 2019-08-21
EP1492554A2 (en) 2005-01-05
US7998477B2 (en) 2011-08-16
JP2005500304A (ja) 2005-01-06
WO2003000014A2 (en) 2003-01-03
US20120282464A1 (en) 2012-11-08
NZ530700A (en) 2009-02-28
EP1492554A4 (en) 2012-07-11
WO2003000014A3 (en) 2004-10-21
US20040219224A1 (en) 2004-11-04
AU2002322295B2 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
IL159475A0 (en) Spherical protein particles, compositions containing the same and methods for the production thereof
AU2002330959A1 (en) Abrasive particles, abrasive articles, and methods of making and using the same
IL162228A0 (en) Shaped nanocrystal particles and methods for making the same
AU2002321872A1 (en) Abrasive particles, and methods of making and using the same
HK1098737A1 (en) Process for the preparation of 1,1,1,3,3-pentafluoro-2-chloropropene and 1,1,1,3,3,3-hexafluoro-2-chloropropane
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
IL164021A (en) Anti-αvβ6 antibodies and their pharmaceutical preparations
HK1079213A1 (en) Anti-il-6 antibodies, compositions, methods and uses
AU2001234693A1 (en) Fused al2o3-y2o3 eutectic abrasive particles, abrasive articles, and methods of making and using the same
IL152918A0 (en) Stabilized tetrazolium-phenazine reagent compositions and methods for using the same
EP1660638A4 (en) LIPOPARTICLES COMPRISING PROTEINS, AND METHODS OF MAKING AND USING SAME LIPOPARTICLES
EP1439017B8 (en) Monodisperse spherical metal particles
AU3281902A (en) Methods for the production of multimeric proteins, and related compositions
AU2002232819A1 (en) Methods for the production of multimeric proteins, and related compositions
IL157846A0 (en) Stable astaxanthin-containing powdery compositions and process for producing the same
IL161893A0 (en) 5-Phenylpyrimidines, agents comprising the same, method for production and use thereof
IL161428A0 (en) Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same
IL157890A0 (en) P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same
HK1061008A1 (en) Spherical alumina particles and production process thereof
EP1539792A4 (en) CNGH0005 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
HK1061009A1 (en) Spherical alumina particles and production process thereof
EP1501870A4 (en) RSV PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES
AU2001234687A1 (en) Fused -al2o3-mgo-y2o3 eutectic abrasive particles, abrasive articles, and methods of making and using the same